March 20th 2025
The session provides an overview of the uninsured population, and also tackles challenges faced by patients when it comes to accessing PAPs.
March 19th 2025
The conference’s first panel offers insight on the current state of awareness among beneficiaries of the Part D cap and Medicare Prescription Payment Plan via the PAN Foundation’s latest research.
March 18th 2025
The conference’s opening session highlights the sector’s current landscape of healthcare coverage and access.
March 17th 2025
Why having these strategies for results—amid disruptions—will be critical to success.
March 4th 2025
The 25% tax on various imports have gone into effect, resulting in retaliatory tariffs from the impacted nations.
EMA entertains relocation bids, readies a business-continuity plan
New location, following Brexit, will be decided in November
Opioid crisis commission issues interim report with numerous calls to action
Meanwhile, opioid manufacturers and distributors contend with multiple DEA penalties
Navigator website for expanded access to developmental drugs is open
Site lists manufacturers’ policies and criteria for experimental access
Consumers’ lack of awareness is a worry for online pharmacy legitimacy
95% of consumers don’t know about online pharmacy certification
FDA schedules public meetings for DSCSA
August, December and February meetings target unresolved technical issues
FDA struggles to react to ‘right to try’ laws
GAO report notes FDA’s 99% acceptance rate for ‘expanded access’, but legislators press on
Managing employee training at the enterprise level
The case for a single enterprise-wide learning management system
Little applause—but little praise—for FDA’s delay of DSCSA enforcement
Late-June announcement gives industry some breathing room for installing product-serialization systems
FDA postpones DSCSA compliance for one year
November 2018 becomes the deadline day for serializing pharma packages
URAC plans a specialty-pharmacy workshop in conjunction with the NASP annual meeting
Specialty pharmacy accreditation attracts growing number of pharmacies
FDA moves to withdraw Opana opioid from the market
Voluntary action—for now; validation of the REMS program
Making a business of ‘compassionate use’ drug distribution
Inceptua Medicines Access carves out a position in supplying pre-approved drugs
Getting ready for MACRA
Healthcare stakeholders ruminate on the effects of MACRA’s alternative payment models
Two drug-pricing firms combine data sets for a deeper picture on reimbursement decisions
Context Matters Inc. and IHS Markit provide analytics on pricing strategies
Survey tracks evolving health economics function in pharma
Cutting Edge report finds continued growth in headcount
Is your corporate board equipped to monitor incentive programs?
Compliance officers at pharma companies need to ensure that the right mechanisms are in place for monitoring sales and business incentives
Scott Gottlieb confirmed as FDA Commissioner
Takes reins with prior experience at both FDA and HHS
HDA’s Origin data service will streamline DSCSA compliance
Wholesaler-led initiative tags ValueCentric to build an industry data repository; sign in for an April 28 webinar
CMOs scramble to get DSCSA compliance in place by November
At Interphex, quick-start programs will be showcased by vendors
QuintilesIMS and Veeva battle over customer master data
QuintilesIMS lawsuit is countered by Veeva’s, claiming antitrust and restraint of trade
US senators question Marathon Pharma’s pricing policy for Emflaza
Rare-disease drug also garnered a valuable pediatric review voucher
FDA’s Office of Generics sets a record of 800+ approvals in 2016
Timely delivery of results will help in GDUFA renewal come October
HHS issues a final rule on 340b policy details
Meanwhile, Congress strategizes repealing Obamacare, which expanded the 340b program
Medical associations, policy groups organize to fight counterfeit drugs and rogue online pharmacies
New consumer-education campaign led by Alliance for Safe Online Pharmacies
Senators wrap up Turing-Valeant hearings on price gouging
A preamble for a next round of legislating drug pricing?
TraceLink survey sees a more complex, less-unified approach to DSCSA
Just released survey details lack of consensus and difficulties with current requirements
More drug-pricing trouble: generic manufacturers are accused of price collusion
Connecticut leads 20 states suing an alleged ring led by Heritage Pharma
There are no counterfeit drugs—only ‘falsified’ ones, opines WHO workgroup
The end of SSFFCs?
Here comes the 21st Century Cures Act
Bills passes House with broad bipartisan support; Senate approval likely
Former Valeant and Philidor executives arrested by DoJ
Upcoming trial could explore the intricacies of ‘alternative fulfillment’ via specialty pharmacies